Zacks Research Issues Negative Forecast for TNXP Earnings

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) – Equities research analysts at Zacks Research decreased their Q2 2026 EPS estimates for Tonix Pharmaceuticals in a research report issued on Wednesday, May 20th. Zacks Research analyst D. Bautz now expects that the company will earn ($2.89) per share for the quarter, down from their prior estimate of ($2.75). The consensus estimate for Tonix Pharmaceuticals’ current full-year earnings is ($9.94) per share. Zacks Research also issued estimates for Tonix Pharmaceuticals’ Q3 2026 earnings at ($2.63) EPS, Q4 2026 earnings at ($2.45) EPS, FY2026 earnings at ($10.80) EPS, FY2027 earnings at ($4.10) EPS and FY2028 earnings at $1.67 EPS.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its earnings results on Monday, May 11th. The company reported ($2.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.54) by ($0.39). Tonix Pharmaceuticals had a negative return on equity of 67.65% and a negative net margin of 839.52%.The company had revenue of $6.88 million for the quarter, compared to analyst estimates of $6.13 million.

TNXP has been the topic of a number of other reports. TD Cowen upgraded shares of Tonix Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, May 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research note on Monday, April 20th. Finally, Wall Street Zen downgraded shares of Tonix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, April 26th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $22.00.

Tonix Pharmaceuticals Stock Performance

Shares of TNXP stock opened at $12.77 on Monday. Tonix Pharmaceuticals has a 1 year low of $11.60 and a 1 year high of $69.97. The firm’s 50 day moving average is $13.75 and its 200-day moving average is $15.45. The firm has a market capitalization of $203.55 million, a price-to-earnings ratio of -0.89 and a beta of 1.68.

Insider Buying and Selling at Tonix Pharmaceuticals

In other Tonix Pharmaceuticals news, CEO Seth Lederman purchased 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 18th. The stock was acquired at an average cost of $14.89 per share, with a total value of $223,350.00. Following the completion of the purchase, the chief executive officer directly owned 15,001 shares in the company, valued at approximately $223,364.89. This represents a 1,500,000.00% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 2.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Tonix Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the business. Bank of America Corp DE raised its stake in shares of Tonix Pharmaceuticals by 101.1% during the first quarter. Bank of America Corp DE now owns 60,958 shares of the company’s stock worth $838,000 after buying an additional 30,644 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Tonix Pharmaceuticals by 26.4% in the first quarter. Bank of New York Mellon Corp now owns 30,426 shares of the company’s stock valued at $418,000 after purchasing an additional 6,362 shares in the last quarter. SJS Investment Consulting Inc. bought a new stake in Tonix Pharmaceuticals in the first quarter valued at approximately $138,000. Man Group plc bought a new stake in Tonix Pharmaceuticals in the fourth quarter valued at approximately $288,000. Finally, Engineers Gate Manager LP increased its stake in Tonix Pharmaceuticals by 63.7% in the fourth quarter. Engineers Gate Manager LP now owns 14,263 shares of the company’s stock valued at $223,000 after purchasing an additional 5,550 shares in the last quarter. 82.26% of the stock is owned by institutional investors.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.